NCT02243592 2026-04-17
Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
National Cancer Institute (NCI)
Active not recruiting
Clinical Trials
157 trialsNCT02911064 2026-04-16
Expectations Regarding Mobility and Self-Care
M.D. Anderson Cancer Center
Active not recruiting
NCT05836857 2026-04-16
The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study
M.D. Anderson Cancer Center
Active not recruiting
NCT02337452 2026-04-15
Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families
M.D. Anderson Cancer Center
Active not recruiting
NCT04464226 2026-04-15
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Phase 3 Active not recruiting
NCT03768336 2026-04-14
A Stress Management and Resiliency Program for Adolescent and Young Adult Survivors
Massachusetts General Hospital
Phase NA Active not recruiting
NCT04958239 2026-04-14
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05611632 2026-04-14
NHS-Galleri
GRAIL, Inc.
Phase NA Active not recruiting
NCT02908906 2026-04-13
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT03148418 2026-04-13
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04606381 2026-04-13
PALOMA
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05155605 2026-04-13
PATHFINDER 2: A Multi-Cancer Early Detection Study
GRAIL, Inc.
Phase NA Active not recruiting
NCT04847466 2026-04-08
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05993299 2026-04-08
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT06703346 2026-04-08
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT05975073 2026-04-07
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen
Phase 1/2 Active not recruiting
NCT05112965 2026-04-06
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05629234 2026-04-06
ROSY-T
AstraZeneca
Phase 3 Active not recruiting
NCT05784766 2026-04-06
SARIC
University of Oklahoma
Phase NA Active not recruiting
NCT02584933 2026-04-02
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Active not recruiting
NCT06018753 2026-04-02
Polaris
Tempus AI
Active not recruiting
NCT06926972 2026-04-01
NOURISH
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Active not recruiting
NCT07321392 2026-03-31
Psychometric Validation of the Psychosocial Assessment Tool in Caregivers of Pediatric Cancer Patients.
Aquà Nadie Se Rinde I.A.P.
Active not recruiting
NCT04050072 2026-03-30
Patient-Reported Outcome Version of the Common Criteria for Adverse Events
St. Jude Children's Research Hospital
Active not recruiting
NCT03809377 2026-03-27
Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects (RTGene 2)
Institute of Cancer Research, United Kingdom
Active not recruiting
NCT04538482 2026-03-27
DINING
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Active not recruiting
NCT00082745 2026-03-19
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
Children's Oncology Group
Active not recruiting
NCT07474168 2026-03-16
T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Zhejiang University
Phase 1 Active not recruiting
NCT04803604 2026-03-12
CASCADE
University of Alabama at Birmingham
Phase NA Active not recruiting
NCT07468422 2026-03-12
OPTin
China Medical University Hospital
Active not recruiting
NCT00001163 2026-03-11
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
National Institutes of Health Clinical Center (CC)
Active not recruiting
NCT05763797 2026-03-11
Developing a Culturally Relevant Supportive Care Program for Black Patients Dealing With Advanced Cancer
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT06864260 2026-03-11
PREEMpT
University of Alabama at Birmingham
Phase NA Active not recruiting
NCT05707910 2026-03-09
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
West China Hospital
Phase 1 Active not recruiting
NCT06549153 2026-03-09
ACT-Together (Acting on Cancer Testing-Together)
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT01428895 2026-03-06
Femoral Bone Metastases
University Health Network, Toronto
Phase NA Active not recruiting
NCT04135794 2026-03-05
MRL1
University Health Network, Toronto
Active not recruiting
NCT00832325 2026-03-03
Adolescent and Young Adult Cancer Survivors: Identity Development
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT04913259 2026-03-03
TS-PAC
Institut Bergonié
Phase NA Active not recruiting
NCT07411105 2026-02-27
CORreCT
Our Lady's Hospice and Care Services
Active not recruiting
NCT02830451 2026-02-25
MTRON
AO Innovation Translation Center
Active not recruiting
NCT03203525 2026-02-25
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07427355 2026-02-23
ASANDE
Alliance For Medical Research in Africa
Active not recruiting
NCT05823740 2026-02-20
Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers
UNC Lineberger Comprehensive Cancer Center
Phase NA Active not recruiting
NCT06754501 2026-02-18
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07093567 2026-02-18
Opiophobia in Adults With Advanced Cancer
M.D. Anderson Cancer Center
Active not recruiting
NCT06340906 2026-02-13
Electroacupuncture in Symptom Management After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
University of California, Irvine
Phase NA Active not recruiting
NCT04078295 2026-02-10
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT07396740 2026-02-09
DISTRO
University Hospital, Brest
Active not recruiting
NCT03260023 2026-02-05
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
Transgene
Phase 1/2 Active not recruiting